Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Assessment of subjective cognitive and emotional effects of antipsychotic drugs. Effect by defect?

Moritz S, Andreou C, Klingberg S, Thoering T, Peters MJ.

Neuropharmacology. 2013 Sep;72:179-86. doi: 10.1016/j.neuropharm.2013.04.039. Epub 2013 May 3.

PMID:
23643756
2.

[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].

Bret P, Bret MC, Queuille E.

Encephale. 2009 Apr;35(2):129-38. doi: 10.1016/j.encep.2008.03.007. Epub 2008 Jul 7. French.

PMID:
19393381
3.

Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.

Fujikawa M, Togo T, Yoshimi A, Fujita J, Nomoto M, Kamijo A, Amagai T, Uchikado H, Katsuse O, Hosojima H, Sakura Y, Furusho R, Suda A, Yamaguchi T, Hori T, Kamada A, Kondo T, Ito M, Odawara T, Hirayasu Y.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):755-60. doi: 10.1016/j.pnpbp.2007.12.002. Epub 2007 Dec 14.

PMID:
18226436
4.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

5.

Predictors of subjective and objective quality of life in outpatients with schizophrenia.

Yamauchi K, Aki H, Tomotake M, Iga J, Numata S, Motoki I, Izaki Y, Tayoshi S, Kinouchi S, Sumitani S, Tayoshi S, Takikawa Y, Kaneda Y, Taniguchi T, Ishimoto Y, Ueno S, Ohmori T.

Psychiatry Clin Neurosci. 2008 Aug;62(4):404-11. doi: 10.1111/j.1440-1819.2008.01818.x.

6.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

7.

Cognitive performance and smoking in first-episode psychosis: the self-medication hypothesis.

Segarra R, Zabala A, Eguíluz JI, Ojeda N, Elizagarate E, Sánchez P, Ballesteros J, Gutiérrez M.

Eur Arch Psychiatry Clin Neurosci. 2011 Jun;261(4):241-50. doi: 10.1007/s00406-010-0146-6. Epub 2010 Sep 14.

PMID:
20839003
8.

How antipsychotics work: the patients' perspective.

Mizrahi R, Bagby RM, Zipursky RB, Kapur S.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):859-64.

PMID:
15908094
9.

Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.

Kitajima R, Miyamoto S, Tenjin T, Ojima K, Ogino S, Miyake N, Fujiwara K, Funamoto Y, Arai J, Tsukahara S, Ito Y, Tadokoro M, Anai K, Kaneda Y, Yamaguchi N.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Mar 30;36(2):300-6. doi: 10.1016/j.pnpbp.2011.11.008. Epub 2011 Nov 21.

PMID:
22122880
10.

Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis.

Azorin JM, Murteira S, Hansen K, Toumi M.

BMC Psychiatry. 2008 Mar 14;8:16. doi: 10.1186/1471-244X-8-16.

11.
12.

The Patient Assessment Questionnaire: initial validation of a measure of treatment effectiveness for patients with schizophrenia and schizoaffective disorder.

Mojtabai R, Corey-Lisle PK, Ip EH, Kopeykina I, Haeri S, Cohen LJ, Shumaker S.

Psychiatry Res. 2012 Dec 30;200(2-3):857-66. doi: 10.1016/j.psychres.2012.06.006. Epub 2012 Jul 26.

PMID:
22840524
13.

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.

Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M.

Acta Psychiatr Scand. 1997 Jan;95(1):40-3.

PMID:
9051159
14.

[Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].

Haefliger T, Bonsack C.

Encephale. 2006 Jan-Feb;32(1 Pt 1):97-105. French.

PMID:
16633296
15.

Psychotropic drug treatment, clinical characteristics and cognitive processing speed in patients with schizophrenia: results from the ELAN study.

Frasch K, Weiser P, Becker T, Längle G, Steinert T, Niederreiner C, Pfiffner C, Jäger S, Bayer W, Eschweiler GW, Kilian R.

Pharmacopsychiatry. 2012 Jun;45(4):138-45. doi: 10.1055/s-0031-1297260. Epub 2011 Dec 15.

PMID:
22174026
16.

Analysis of differential clinical profiles of different antipsychotic molecules in the first psychotic episode: a retrospective study.

Spanarello S, Beoni AM, Mina G, Amantini K, Colotto A.

Encephale. 2005 Nov-Dec;31(6 Pt 1):692-7.

PMID:
16462688
17.
18.

Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study.

Levine SZ, Rabinowitz J, Case M, Ascher-Svanum H.

J Clin Psychopharmacol. 2010 Aug;30(4):446-9. doi: 10.1097/JCP.0b013e3181e68e80.

PMID:
20631562
19.

Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.

Elie D, Poirier M, Chianetta J, Durand M, Grégoire C, Grignon S.

J Psychopharmacol. 2010 Jul;24(7):1037-44. doi: 10.1177/0269881108100777. Epub 2009 Jan 22.

PMID:
19164494
20.

Duration of untreated psychosis and cognitive functioning in first-episode patients.

Norman RM, Townsend L, Malla AK.

Br J Psychiatry. 2001 Oct;179:340-5.

Supplemental Content

Support Center